Treatment Details – 17.8 months
|Patients: This Phase II study involved 27 patients with advanced malignant pleural mesothelioma.|
Treatment: The treatment consisted of a combination of hyperthermia with three chemotherapy drugs – ifosfamide (IFEX), carboplatin (paraplatin), and etoposide (vepesid).
Toxicity: There was one death associated with progressive disease and sepsis. Other toxicities included hematologic (grades 1-4), gastrointestinal (grades 1-3), nausea and vomiting (grades 1-3), hepatic (grades 1-2), skin (grade 3), and renal (grades 1-2). In addition, there were two cardiac complications during hyperthermia.
Results: Median survival was 76.6 weeks (17.8 months).
Correspondence: A.Bakhshandeh, MD